This study is a triple-blind, placebo-controlled, randomized controlled trial of 120 adults that will evaluate the impact of a novel nutritional supplement on improving nutrient gaps and changing nutrient status and the gut microbiome among glucagon-like peptide-1 receptor agonist (GLP-1 RA) users.
Be male or female
Be aged 18-59.
Has a BMI between 20-31.9.
Anyone currently taking GLP-1 medication at their maintenance dose (week 8+), and without any plans to alter their dosage. This includes: Semaglutide (Ozempic®, Wegovy®, Rybelsus®), Liraglutide (Saxenda®, Victoza®), Dulaglutide (Trulicity®), Exenatide (Byetta®, Bydureon®), Lixisenatide (Adlyxin®)
Anyone with a diagnosis of Type I or Type II diabetes.
Anyone with a diagnosis of any metabolic health condition, such as hypertension and dyslipidemia.
Anyone who has taken any multivitamin/multimineral supplements within the past 3 months.
Anyone who has taken a probiotic supplement within the past month.